PBAC to consider pan-tumour indications for immunotherapy

A special meeting of PBAC will be held on 17 August to consider options for PBS listing of PD-L1 immunotherapies across multiple tumour indications. Equity of access to immunotherapies has dominated cancer medicines discussions since they first became available and shown to transform management of cancers with previously dismal prognosis such as advanced melanoma. Last ...

Already a member?

Login to keep reading.

© 2022 the limbic